Since we have also observed a concomitant decrease in nucleolin binding to ErbB2 both in vitro and in vivo, it is plausible to assume that the anti-cancer effects of GroA were mediated by the disruption of ErbB2–nucleolin complexes. This evidence concerns the gene NUCLEOLIN and cancer.